Tonix Pharmaceuticals Holding Corp. - Common Stock (TNXP)
14.00
+0.98 (7.53%)
Tonix Pharmaceuticals Holdings is a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system disorders and other serious medical conditions
The company is dedicated to advancing its pipeline of product candidates, which include treatments for conditions such as migraines, post-traumatic stress disorder, and various infectious diseases. By leveraging its expertise in drug development and utilizing strategic collaborations, Tonix aims to bring novel treatment options to market that address unmet medical needs and improve patient outcomes.
Tonix Pharmaceuticals (NASDAQTNXP) has been awarded a grant from the Medical CBRN Defense Consortium (MCDC) to advance the development of TNX-801, a recombinant horsepox virus-based live vaccine for mpox and smallpox. The funding will support market analysis, target market identification, and commercialization planning for both private and government sectors. TNX-801 is designed as a single-dose vaccine with long-term protection and improved tolerability compared to older vaccinia-based vaccines. Preclinical studies have demonstrated its effectiveness against monkeypox, offering potential global benefits amid ongoing outbreaks of clade I mpox.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.
Wondering how the US markets performed one hour before the close of the markets on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Tonix Pharmaceuticals (NASDAQTNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced that Jessica Morris, chief operating officer, will present at the 2025 Virtual Investor Summit on March 11, 2025, at 10:30 a.m. ET. Investors interested in scheduling a virtual meeting with management during the event should contact the Investor Summit conference coordinator.
Wheaton Precious Metals (NYSEWPM) (TSX: WPM) announced ReThink Milling Inc. as the winner of its inaugural Future of Mining Challenge, awarding the company $1 million for its Conjugate Anvil Hammer Mill (CAHM) and MonoRoll technologies. These innovations aim to enhance milling efficiency while significantly reducing energy consumption, greenhouse gas emissions, and operating costs. Wheaton launched the challenge in September 2024 to identify scalable solutions for improving sustainability in mining. CEO Randy Smallwood emphasized the importance of industry support in advancing new technologies, while ReThink Milling expressed excitement for the next phase of commercialization.
Tonix Pharmaceuticals (NASDAQTNXP) released selected preliminary financial results for 2024, reporting approximately $98.8 million in cash and cash equivalents as of Dec. 31. Net cash used in operations declined to $60.9 million from $102 million the prior year, while net revenue rose to $10.1 million from $7.8 million. The company recorded a net operating loss of $126.6 million, including $59 million in non-cash impairment charges. Tonix repaid its mortgage on Feb. 3, 2025, becoming debt-free, and expects its cash resources and recent fundraising to support operations into early 2026, covering the FDA’s Aug. 15, 2025, PDUFA decision date for TNX-102 SL in fibromyalgia management.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.
Tonix Pharmaceuticals (NASDAQTNXP) announced positive topline results from its Phase 1 trial of TNX-1500, an Fc-modified humanized anti-CD40L monoclonal antibody, in healthy participants. The study demonstrated TNX-1500 was well tolerated, with no serious adverse events or thromboembolic complications, and effectively blocked immune responses at higher doses. The pharmacokinetics support monthly dosing at 10 mg/kg or above, positioning the drug as a potential best-in-class therapy for preventing organ transplant rejection and treating autoimmune diseases. Tonix plans to discuss these findings with the FDA in preparation for a Phase 2 study in kidney transplant recipients.
Tonix Pharmaceuticals (NASDAQTNXP) announced that its President and CEO, Seth Lederman, M.D., will present at the BIO CEO & Investor Conference on Feb. 10, 2025, at 1:45 p.m. ET in New York City. The company, which develops biopharmaceutical products, invites investors to arrange meetings with management through the conference’s registration platform.
Tonix Pharmaceuticals (NASDAQTNXP) announced the promotion of Siobhan Fogarty to chief technical officer. Fogarty, who joined Tonix in 2016, previously served as executive vice president of product development and has over 25 years of experience in pharmaceutical and biotech product development, manufacturing and quality. Her promotion comes as the company prepares for the U.S. Food and Drug Administration’s Aug. 15, 2025, decision on TNX-102 SL, a non-opioid treatment for fibromyalgia. Fogarty’s expertise spans small molecules, biologics and live-virus vaccines, having held leadership roles at Elan Corporation, GlaxoSmithKline, Fuisz Technologies and Biovail Corporation.
Stay updated with the latest market activity on Monday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
